Status:
COMPLETED
AZD6765 Severe Major Depressive Disorder (MDD) IV
Lead Sponsor:
AstraZeneca
Conditions:
Major Depressive Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of this research study is to determine whether AZD6765 has an effect on the patient's depression when taken together with current depression medication. In addition, information will be ga...
Eligibility Criteria
Inclusion
- Signed informed consent before any study-related procedures start.
- The patient is previously diagnosed with Major Depressive Disorder (MDD) and currently taking an antidepressant for at least 6 weeks.
- Patient has a history of poor response to 1 or more antidepressants (in addition to the antidepressant the patient is taking at enrollment) after exposure at adequate doses or maximum tolerated doses for ≥4 weeks.
Exclusion
- Patient has a lifetime history of schizophrenia, bipolar, psychosis or psychotic depression.
- Patient has a lifetime history of failure to ECT therapy.
- Patient is pregnant or breast feeding.
- Length of current episode of depression exceeds ≥2 years.
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2010
Estimated Enrollment :
152 Patients enrolled
Trial Details
Trial ID
NCT00781742
Start Date
October 1 2008
End Date
March 1 2010
Last Update
July 25 2012
Active Locations (27)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Little Rock, Arkansas, United States
2
Research Site
Los Angeles, California, United States
3
Research Site
Orange, California, United States
4
Research Site
San Diego, California, United States